bluebird bio acquires Precision Genome Engineering bluebird bio announced the acquisition of Precision Genome Engineering, or Pregenen, a privately held biotechnology company headquartered in Seattle, Washington. Pregenen is a leader in the development of gene editing and cell signaling technologies with a broad range of potential therapeutic applications. Under the terms of the agreement, bluebird bio issued the former stakeholders of Pregenen 408,667 shares of bluebird common stock at closing, and paid or assumed approximately $4.9M of current liabilities of Pregenen and its stakeholders. The former stakeholders of Pregenen are also eligible to receive up to an additional $15M in cash upon the achievement of certain preclinical milestones as well as $20.1M in cash upon achievement of certain clinical milestones and $99.9M in cash upon the achievement of certain commercial milestones with respect to product candidates identified using Pregenenís technology.
News For BLUE From The Last 14 Days
Check below for free stories on BLUE the last two weeks.